Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) — Cash Flow-to-Debt Ratio
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a Cash Flow-to-Debt Ratio of 0.08x as of September 2025, meaning its operating cash flow of CN¥11.57 Million could theoretically repay 0% of its total liabilities (CN¥142.19 Million) in one year. Check Hubei Biocause Heilen Pharmaceutical Co. (301211) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Hubei Biocause Heilen Pharmaceutical Co. Ltd. across 9 annual periods. Also explore Hubei Biocause Heilen Pharmaceutical Co. assets under control for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2025)
Year-by-year debt coverage analysis for Hubei Biocause Heilen Pharmaceutical Co. Ltd.. For market capitalisation and broader financial context, see 301211 market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.06x | CN¥7.55 Million | CN¥128.65 Million | ▼ -89.1% |
| 2024 | 0.54x | CN¥96.07 Million | CN¥178.97 Million | ▼ -25.6% |
| 2023 | 0.72x | CN¥137.06 Million | CN¥189.89 Million | ▼ -36.3% |
| 2022 | 1.13x | CN¥250.79 Million | CN¥221.22 Million | ▼ -1.7% |
| 2021 | 1.15x | CN¥123.98 Million | CN¥107.53 Million | ▼ -2.5% |
| 2020 | 1.18x | CN¥121.67 Million | CN¥102.85 Million | ▼ -18.2% |
| 2019 | 1.45x | CN¥372.33 Million | CN¥257.31 Million | ▲ +356.5% |
| 2018 | 0.32x | CN¥76.18 Million | CN¥240.36 Million | ▲ +210.1% |
| 2017 | -0.29x | CN¥-65.44 Million | CN¥227.25 Million | — |